Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of “Buy” from Analysts

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have earned a consensus rating of “Buy” from the seventeen analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and four have issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $54.3571.

Several research analysts recently commented on SRRK shares. BMO Capital Markets increased their price objective on Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $58.00 target price on shares of Scholar Rock in a report on Tuesday, March 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. JPMorgan Chase & Co. raised their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. Finally, UBS Group initiated coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target on the stock.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $44.64 on Monday. Scholar Rock has a 12 month low of $22.71 and a 12 month high of $49.82. The stock has a 50 day moving average of $45.18 and a two-hundred day moving average of $40.00. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. The firm has a market cap of $5.13 billion, a P/E ratio of -13.01 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period in the previous year, the company posted ($0.64) earnings per share. On average, analysts expect that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mo Qatanani sold 14,898 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total transaction of $695,885.58. Following the transaction, the insider directly owned 85,660 shares in the company, valued at $4,001,178.60. The trade was a 14.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Akshay Vaishnaw sold 20,438 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $872,702.60. Following the completion of the sale, the insider owned 595,767 shares of the company’s stock, valued at $25,439,250.90. This trade represents a 3.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 207,464 shares of company stock worth $9,157,423. 13.30% of the stock is currently owned by insiders.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the stock. IFP Advisors Inc raised its holdings in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Scholar Rock in the fourth quarter valued at about $30,000. Summit Securities Group LLC purchased a new stake in shares of Scholar Rock in the fourth quarter valued at about $31,000. Ramirez Asset Management Inc. acquired a new stake in Scholar Rock during the third quarter worth about $37,000. Finally, EverSource Wealth Advisors LLC raised its stake in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).